Jaguar Health Inc

Jaguar Health Inc Stock Forecast & Price Prediction

Live Jaguar Health Inc Stock (JAGX) Price
$1.1

1

Ratings

  • Buy 1
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$1.1

P/E Ratio

0.24

Volume Traded Today

$76,258

Dividend

Dividends not available for JAGX

52 Week High/low

17.70/0.05

Jaguar Health Inc Market Cap

$10.8M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $JAGX ๐Ÿ›‘

Before you buy JAGX you'll want to see this list of ten stocks that have huge potential. Want to see if JAGX made the cut? Enter your email below

JAGX Summary

The Jaguar Health Inc (JAGX) share price is expected to increase by 1218.18% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered JAGX. Price targets range from $14.5 at the low end to $14.5 at the high end. The current analyst consensus for JAGX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

JAGX Analyst Ratings

About 1 Wall Street analysts have assigned JAGX 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Jaguar Health Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on JAGX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

JAGX stock forecast by analyst

These are the latest 20 analyst ratings of JAGX.

Analyst/Firm

Rating

Price Target

Change

Date

Louise Chen
Cantor Fitzgerald

Overweight

$5

Initiates

Jul 7, 2021

H.C. Wainwright

Buy


Reiterates

Nov 25, 2020

Ladenburg Thalmann

Buy


Initiates

Nov 25, 2020

Rodman & Renshaw

Buy


Initiates

Nov 25, 2020

Aegis Capital

Buy


Initiates

Nov 25, 2020

HC Wainwright & Co.

Buy

$3

Reiterates

Nov 18, 2019

H.C. Wainwright

Buy


Reiterates

Nov 18, 2019

Ladenburg Thalmann

Buy


Initiates

Sep 12, 2019

Rodman & Renshaw

Buy


Initiates

Jul 11, 2017

Aegis Capital

Buy


Initiates

Nov 12, 2015

JAGX Company Information

  • Company Name: Jaguar Health, Inc.
  • Business Stage: Commercial stage pharmaceuticals company
  • Focus: Developing plant-based prescription medicines for gastrointestinal distress, particularly chronic diarrhea
  • Segments: Operates through two segments - Human Health and Animal Health
  • Key Products:
    • Mytesi: Anti-secretory antidiarrheal drug for non-infectious diarrhea in adults with HIV/AIDS
    • Canalevia-CA1: Prescription drug for chemotherapy-induced diarrhea in dogs
  • Clinical Trials:
    • Crofelemer: In Phase 3 for diarrhea prophylaxis in adult cancer patients, addressing rare/orphan diseases
    • NP-300: Second-generation antidiarrheal drug for moderate-to-severe diarrhea
  • Headquarters: San Francisco, California
JAGX
Jaguar Health Inc (JAGX)

When did it IPO

2015

Staff Count

49

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Ms. Lisa A. Conte

Market Cap

$10.8M

Jaguar Health Inc (JAGX) Financial Data

In 2023, JAGX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that JAGX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$9.4M

Revenue From 2021

$4.3M

-53.81 %
From Previous Year

Revenue From 2022

$12.0M

175.80 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $10.2M
  • Operating Margin TTM -264.5%
  • Gross profit TTM $0
  • Return on assets TTM -34.5%
  • Return on equity TTM -290.9%
  • Profit Margin 0.0%
  • Book Value Per Share 2.16%
  • Market capitalisation $10.8M
  • Revenue for 2021 $4.3M
  • Revenue for 2022 $12.0M
  • Revenue for 2023 N/A
  • EPS this year (TTM) $4.79

Jaguar Health Inc (JAGX) Latest News

No news data available.

...

JAGX Frequently asked questions

The highest forecasted price for JAGX is $14.5 from at .

The lowest forecasted price for JAGX is $14.5 from from

The JAGX analyst ratings consensus are 1 buy ratings, 0 hold ratings, and 0 sell ratings.